ArticleGut and liver2020
Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Guidance and Monitoring of Endoscopic Radiofrequency Ablation.
Article in Gut and liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Contrast-Enhanced Low-Mechanical-Index Endoscopic Ultrasound for the Evaluation of Focal Liver Lesions.Diagnostics (Basel, Switzerland) · 2026Review
- Contrast-enhanced endoscopic ultrasound-guided additional ethanol ablation after early detection of occult residual pancreatic insulinoma.Endoscopy · 2026Article
- Role of endoscopic ultrasound in the treatment of pancreatic neuroendocrine tumors: Lights and shadows of endoscopic ultrasound-guided radiofrequency ablation.World journal of gastrointestinal endoscopy · 2026Review
- Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic neoplasms: a comprehensive review.Frontiers in medicine · 2026Review
- Review
- Role of endoscopic ultrasound in the diagnosis and local ablative therapy of pancreatic neuroendocrine tumors.The Korean journal of internal medicine · 2025Review
- Endoscopic Ultrasound-Guided Locoregional Treatments for Pancreatic Neuroendocrine Neoplasms.Current oncology (Toronto, Ont.) · 2025Review
- Endoscopic-Ultrasound-Guided Radiofrequency Ablation for Pancreatic Tumors.Journal of clinical medicine · 2025Review
- Advances in Endoscopic Ultrasonography-Based Diagnosis of Pancreatic Lesions: Narrative Review.Cancers · 2025Review
- Endoscopic Ultrasound-Guided Pancreatic Tissue Sampling: Lesion Assessment, Needles, and Techniques.Medicina (Kaunas, Lithuania) · 2024Review
- Percutaneous Ultrasound-Guided Radiofrequency Ablation as a Therapeutic Approach for the Management of Insulinomas and Associated Metastases in Dogs.Animals : an open access journal from MDPI · 2024Article
- EUS-Guided Radiofrequency Ablation Therapy for Pancreatic Neoplasia.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Contrast-enhanced guided endoscopic ultrasound procedures.World journal of gastroenterology · 2024Review
- Review
- Contrast-enhanced harmonic EUS-guided radiofrequency ablation of hepatocellular carcinoma: a new horizon in endohepatology.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2023Article
- Approaching Small Neuroendocrine Tumors with Radiofrequency Ablation.Diagnostics (Basel, Switzerland) · 2023Review
- Current status of the role of endoscopy in evaluation and management of gastrointestinal and pancreatic neuroendocrine tumors.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Review
- Image Fusion Involving Real-Time Transabdominal or Endoscopic Ultrasound for Gastrointestinal Malignancies: Review of Current and Future Applications.Diagnostics (Basel, Switzerland) · 2022Review
- Gastric Cancer Angiogenesis Assessment by Dynamic Contrast Harmonic Imaging Endoscopic Ultrasound (CHI-EUS) and Immunohistochemical Analysis-A Feasibility Study.Journal of personalized medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Interventional endoscopists may utilize contrast-enhanced harmonic endoscopic ultrasound (CEHEUS) for image guidance during radiofrequency ablation (RFA) because of its capability to delineate real-time tumor perfusion dynamics. The purpose of this study was to assess the utility of CEH-EUS for the guidance and monitoring of endoscopic RFA. Methods: Nineteen consecutive patients with solid abdominal tumors who underwent CEH-EUS and endoscopic RFA were included. The extent of the ablation was assessed by CEH-EUS at 5 to 7 days after RFA. Additional RFAs were performed under CEH-EUS guidance. Results: The diagnoses were as follows: nonfunctioning neuroendocrine tumor (n=13), solid pseudopapillary neoplasm (SPN) (n=2), insulinoma (n=1), left adrenal adenoma (n=2), and left adrenal oligometastasis (n=1). Pre-CEH-EUS findings revealed that 17 cases showed hyperenhanced patterns and two cases of SPN showed isoenhanced patterns. CEH-EUS-assisted RFA was technically feasible in all 19 patients. After the first RFA session, seven patients of the treated tumors showed the disappearance of intratumoral enhancement on CEH-EUS, whereas 12 showed residual contrast enhancement. Twelve patients with incomplete ablation were further treated with additional RFA under real-time CEH-EUS guidance. Radiologic complete response was observed in 13 patients (68.4%). Among the 35 ablation procedures, the only adverse events were two episodes of pancreatitis (5.7%; 1 moderate and 1 mild). During the median follow-up of 28 months, the local recurrence rate was 7.7%. Conclusions: The application of CEH-EUS for RFA could be helpful in assessing early treatment response after ablation and targeting residual viable tumors during additional ablation sessions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.